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enetic factors for many decades have been
known to play a critical role in the etiology of
diabetes, but it has been only recently that the
speciﬁc genes have been identiﬁed. The identi-
ﬁcation of the underlying molecular genetics opens the
possibility for understanding the genetic architecture of
clinically deﬁned categories of diabetes, new biological
insights, new clinical insights, and new clinical applica-
tions. This article examines the new insights that have
arisen from deﬁning the etiological genes in monogenic
diabetes and the predisposing polymorphisms in type 2
diabetes.
MONOGENIC DIABETES
Deﬁning monogenic diabetes genes by candidate
gene and positional cloning approaches. There has
been rapid progress in deﬁning the etiological genes for
monogenic diabetes reﬂecting the relative simplicity of
gene discovery in single gene disorders. The candidate
gene approach has been remarkably successful in deﬁning
monogenic genes; this reﬂects that key rate-limiting steps
in insulin secretion and action are known, and severe
mutations affecting these proteins will result in -cell
dysfunction or insulin resistance. Examples of this ap-
proach include the genes encoding insulin (1), glucokinase
(2,3), the two ATP-sensitive K
 channel (KATP channel)
subunits Kir6.2 (4) and SUR1 (5,6), peroxisome prolifera-
tor–activated receptor (PPAR) (7), and the insulin recep-
tor (8). Finding human subjects with mutations in these
candidate genes has allowed conﬁrmation of a critical role in
humans of the encoded protein, helped deﬁne structure and
function of the protein, and allowed conﬁrmation of the
associated pathophysiology (e.g., abnormal glucose sensing
in glucokinase mutations) (9), but it has not led to the
identiﬁcation of novel pathways in glucose homeostasis.
Completely unexpected critical pathways for insulin
secretion and action have resulted from the positional
cloning of novel monogenic diabetes genes. The most
striking example was the identiﬁcation of HNF1A, encod-
ing the transcription factor hepatic nuclear factor (HNF)-
1, as the maturity-onset diabetes of the young (MODY)
gene linked to 12q (10). Before this ﬁnding it was not
known that HNF1A was expressed in the -cell, and
diabetes had not been noticed in the hnf1a-knockout
mouse (11), although it was noticed subsequently (12).
This result rapidly led to mutations in other hepatic
transcription factor genes, HNF4A (13) and HNF1B (14),
shown to cause MODY. These ﬁndings have led to a whole
new area of -cell biology seeking to explain why haplo-
insufﬁcency of these genes resulted in progressive -cell
dysfunction (15,16). Mutations in CEL, which encodes the
lipolytic enzyme carboxyl-ester lipase, responsible for the
hydrolysis of cholesterol esters, was also an unexpected
MODY gene identiﬁed through positional cloning (17).
CEL is only expressed in the pancreatic acinar cell, so it
was unexpected that there was -cell dysfunction. Further
studies of the mechanism will lead to new understanding
of the close relationship between the exocrine and endo-
crine pancreas. Familial partial lipodystrophy was shown,
following linkage to 1q21, to arise from mutations in
LMNA, encoding Lamin A/C (18). Mutations in LMNA can
also result in myopathy, dilated cardiomyopathy, or atyp-
ical progeria (19), and the biology of how these mutations
alter fat distribution is still incompletely understood.
Therefore, positional cloning has led to exciting novel
pathways of glucose homeostasis.
Most monogenic diabetes genes are -cell genes. A
key result has been that the vast majority of genes where
mutations cause early-onset diabetes have reduced -cell
function rather than increased insulin resistance. Het-
erozygous haploinsufﬁcency results in dominant early-
onset diabetes for many -cell genes, including GCK,
HNF1A, HNF4A, and HNF1B, but this is not seen in insulin
resistance genes. This shows that even when faced with
severe insulin resistance, a healthy -cell is usually able to
compensate, but there is no compensation possible when
faced with marked insulin deﬁciency. There are many mech-
anisms of -cell dysfunction seen in monogenic diabetes,
including reduced -cell development, failure of glucose
sensing, and increased destruction of the -cell (Table 1).
Gene discovery can also lead to recognition of novel
phenotypes. For many genetic syndromes, such as Wol-
cott Rallison, and IPEX (immune dysregulation, polyendo-
crinopathy, enteropathy, X-linked) syndromes, a discrete
cluster of clinical features including diabetes was initially
recognized as a clinical syndrome, and subsequently the
gene responsible was identiﬁed (20,21). In these cases, the
gene discovery gave new biological insights but only
limited insights into the phenotype.
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identiﬁcation of the etiological genes helped the recogni-
tion of novel clinical subgroups. MODY was clinically
deﬁned as autosomal dominantly inherited, non–insulin-
dependent, early-onset diabetes, but now there are at least
eight genetic subgroups of MODY, most of which have a
discrete phenotype (Fig. 1) (22,23). Similarly, diabetes
diagnosed in the ﬁrst few months of life was deﬁned
clinically as permanent neonatal diabetes mellitus
(PNDM) or transient neonatal diabetes mellitus (TNDM),
depending on whether the diabetes resolved (22,23). Mo-
lecular genetic advances have identiﬁed three genetic
subgroups of TNDM, four genetic subgroups of PNDM,
and ﬁve genetic syndromes that include neonatal diabetes
(Fig. 2); many of these genetically deﬁned subgroups can,
at least in part, be separated by their clinical features
(22,23).
Many entirely novel multisystem clinical syndromes
were only recognized clinically after the molecular genet-
ics were deﬁned. The most common is maternally inher-
ited diabetes and deafness, resulting from a heteroplasmic
mitochondrial gene mutation at position 3243, which was
recognized when the gene was identiﬁed in a single large
Dutch family (24). Patients with this mitochondrial muta-
tion not only have diabetes typically diagnosed in early
adult life and sensorineural deafness, but also other
features resulting from the associated mitochondrial
dysfunction including myopathy, pigmented retinopa-
thy, cardiomyopathy, and focal glomerulosclerosis
(25,26). Prevalence studies have suggested that 3243 ac-
counts for 1–2% of diabetes in Japanese and 0.2–0.5% in
European series (26). Mutations in the transcription factor
HNF1B mutations were ﬁrst described as a subgroup of
MODY (14), but it was quickly realized that the most
consistent feature was renal cysts (27–29); therefore, the
novel syndrome renal cysts and diabetes was proposed
(30). Further studies have shown that heterozygous muta-
tions or whole gene deletions (31) of this ubiquitous
transcription factor result in a wide range of developmen-
tal kidney disease and other features including uterine and
genital abnormalities, gout, hyperuricemia, exocrine pan-
creatic dysfunction, abnormal liver function tests, and
insulin resistance (32).
Clinical features reﬂect the function of the encoded
protein outside glucose regulation. One striking example
of how extra pancreatic features give new insights into the
role of the encoded proteins is the way in which birth
weight is affected in the different genetic subtypes of
MODY (Fig. 3). In utero fetal insulin is a major growth
factor, and therefore altered fetal insulin secretion will
alter birth weight. Increased birth weight resulting from
increased fetal insulin secretion in response to maternal
hyperglycemia may be seen in all types of diabetes includ-
ing monogenic diabetes. A key additional feature of mo-
nogenic diabetes is that if the genes alter fetal insulin
secretion or fetal insulin action in utero, birth weight is
also altered (33).
Because patients with glucokinase mutations have mod-
erate stable hyperglycemia in the neonatal period (34), it is
expected that the glucose sensing abnormality was also
present in utero, resulting in reduced fetal insulin secre-
tion and reduced birth weight by 550 g (35). Conversely, in
HNF1A mutations, where glucose tolerance is normal at
birth and diabetes rarely develops before adolescence,
-cell function was likely to have been normal in utero,
hence fetal HNF1A mutations would have no impact on
birth weight (38). The marked reduction in birth weight
(900 g) with fetal HNF1B mutations (36) suggests that
fetal insulin secretion is disrupted even though diabetes
TABLE 1
Examples of some mechanisms of -cell dysfunction seen in
monogenic diabetes
Mechanism of -cell dysfunction Gene/mutation
Reduced -cell number
Pancreatic aplasia IPF1 homozygous
PTF1A
Reduced -cell development HNF1B
Reduced metabolism
Reduced glucose sensing GCK
Reduced metabolism Mitochondrial mutations
HNF1A
HNF1B
HNF4A
IPF1 heterozygous
Failure to depolarise membrane
Failure to close KATP channel KCNJ11
ABCC8
Increased destruction of -cells
Immune-mediated destruction FOXP3
INS
Endoplasmic reticulum stress EIF2AK3
WFS1
Increased apoptosis cause
uncertain
HNF1A
HNF4A
Mitochondrial mutations
MODY
11%
MODY X
66%
Transcription factors
22%
GCK
2%
HNF1B
61%
HNF1A
4%
HNF4A
<1%
IPF1
<1%
NeuroD1
<1%
INS
<1%
CEL
FIG. 1. The genetic heterogeneity of clinically deﬁned MODY. The
percentages given are based on over 1,000 referrals to the Exeter lab
for genetic testing in MODY. (S. Ellard and A.T.H., unpublished data).
MODY X represents patients with a clear clinical diagnosis of MODY
who do not have a mutation in any of the known genes.
Neonatal diabetes
45%
Permanent
(PNDM)
45%
Transient
(TNDM)
ABCC8 6q ZAC KCNJ11 INS
PTF1A
FOXP3
EIF2AK3
HNF1B
IPF1
10%
Syndromes
& Pancreatic
aplasia
GCK
71%
11% 15%
31%
13% 16%
3%
45%
FIG. 2. The genetic heterogeneity of the clinically deﬁned subdivisions
of neonatal diabetes. The percentages given are based on over 400
referrals to the Exeter and Salisbury labs for genetic testing for
neonatal diabetes (S. Ellard, A.T.H., D. Mackay, and I.K. Temple,
unpublished data). KCNJ11, ABCC8, INS, and HNF1B mutations are
dominantly acting; GCK, PTF1A, EIF2AK3, IPF1, and some INS and
ABCC8 mutations are recessively acting; FOXP3 is sex linked; and the
6q ZAC region for TNDM results from altered imprinting at this locus.
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with the role of the fetal -cell. HNF1- is a critical
transcription factor in the maturation of the pancreatic
stem cell before differentiation into the exocrine and
endocrine cells (37). A marked increase in birth weight
(790 g) seen with a fetal HNF4A mutation, even when
inherited from the father, is an unexpected ﬁnding (38).
Macrosomia reﬂects increased insulin secretion (38), and
some neonates with HNF4A mutations have transient (38)
or prolonged hypoglycemia (39). This means that in-
creased insulin secretion in the fetus progresses to re-
duced insulin secretion in adolescence or early adulthood.
This pattern is also seen in some dominant SUR1 muta-
tions (40).
Deﬁning genetic etiology can alter treatment. Genet-
icists have long argued that deﬁning the etiology of sub-
groups of diabetes should help the development of
appropriate treatment, and in monogenic diabetes there
are now clear examples of this (41).
The best example of pharmacogenetics has been in the
treatment of patients with PNDM resulting from mutations
in the Kir6.2 and SUR1 subunits of the KATP channel. These
patients frequently present with ketoacidosis and no de-
tectable endogenous insulin secretion, and therefore insu-
lin injections are the only treatment option. Insulin
treatment is difﬁcult in a young child, and outstanding
glycemic control is rarely achieved. Finding that one-third
of the patients with PNDM had mutations in the Kir6.2
channel that reduced channel closure in response to ATP
led to the possibility of treating these patients with sulfo-
nylureas that close the channel by an ATP-independent
route (4,42). It was then possible to replace insulin injec-
tions with high-dose oral sulfonylureas in 90% of patients
and also to achieve improved glycemic control without an
increase in hypoglycemia (43,44). Insulin secretion is
regulated despite the -cell having a limited response to
ATP; this is predominantly mediated through nonclassical
pathways for insulin secretion, particularly GLP1 (43).
Excellent glycemic control is also seen in the majority of
patients with SUR1 mutations treated with sulfonylureas
(45). Therefore, 50% of patients diagnosed before 6
months with permanent diabetes can beneﬁt greatly from
a molecular diagnosis. To date, patients with KATP channel
mutations have maintained near normoglycemia for over 4
years (A.T.H., unpublished data). Doses tend to reduce
over time, suggesting that the effectiveness of this treat-
ment will be long lasting.
There is also clear evidence of pharmacogenetics within
the genetic subcategories of MODY. The fall in fasting
glucose with sulfonylurea therapy is fourfold greater in
HNF1A MODY patients compared with glycemia- and
BMI-matched type 2 diabetic subjects (46). This sensitivity
to sulfonylureas frequently means that patients who have
been misdiagnosed as type 1 diabetic and treated with
insulin from diagnosis can successfully transfer to sulfo-
nylureas without deterioration in glycemic control (47).
This improved hypoglycemic response to sulfonylureas
compared with that in type 2 diabetes represents, in part,
greater insulin secretion (46). Animal and cellular models
of HNF-1 deﬁciency have suggested that the major defect
in the -cell is in glucose metabolism, which may explain
why these subjects are very responsive to a drug that binds
to the KATP channel, which is downstream of glucose
metabolism. Pharmacogenetics may result from a speciﬁc
genetic subgroup having reduced instead of increased
response to a drug. In HNF1B MODY there is reduced
pancreatic size (48), reﬂecting reduced development of the
endocrine and exocrine pancreas (37). In these patients,
treatment with sulfonylureas is relatively unsuccessful and
insulin treatment is rapidly required (49). In GCK MODY
patients, glucose is regulated to remain at a higher fasting
level, hence oral hypoglycemic agents or low/moderate-
dose insulin does not alter glycemia. In 24 GCK MODY
patients on insulin or oral hypoglycemic agents, A1C was
6.3% on treatment and 6.3% after 3 months off treatment
(O. Gill-Carey and A.T.H., unpublished data).
Introduction of monogenic diabetes testing into clin-
ical practice. Guiding treatment decisions is not the only
clinical role for genetic information in monogenic diabe-
tes; it can also be used to make a deﬁnitive diagnosis,
explain the cluster of clinical features, and predict the
clinical course (26). The clear clinical utility of this has led
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FIG. 3. The impact on birth weight of a fetus inheriting the four most common MODY gene mutations. Birth weight is presented as centile birth
weight with the fetus inheriting the mutation in blue and in comparison a fetus without the mutation in green. Data are from refs. 35, 36, and 38.
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clinical practice with noncommercial and commercial
diagnostic services for monogenic diabetes (50). Guide-
lines for laboratories offering this testing have now been
produced (51). As this is a new area of diabetes practice,
guidelines are also needed for both patients and physi-
cians (22), and websites such as www.diabetesgenes.org
offer both educational material and guidelines about who
should be tested. As the costs of genetic testing fall and more
advantages are established, genetic testing to detect mono-
genic diabetes will increase in clinical practice.
LESSONS LEARNED FOR MULTIFACTORIAL DISEASE
Monogenic and syndromic forms account for only a small,
though highly informative, proportion of cases of nonau-
toimmune diabetes. The challenge for medical science lies
in bringing equivalent mechanistic insights and transla-
tional beneﬁts to the hundreds of millions of people
already affected by, or at risk of, more common, typical
forms of diabetes. For type 2 diabetes, there is abundant
evidence that individual susceptibility is inﬂuenced by
both the combination of genetic variation at multiple sites
and a series of environmental exposures encountered
during life (52). Tracking down the speciﬁc genetic vari-
ants involved has been tougher than for monogenic forms
of disease, since the correlations between genotype and
phenotype are far weaker (53,54). However, recent efforts
have now identiﬁed at least 17 conﬁrmed type 2 diabetes–
susceptibility variants (Table 2) (55–67), a count certain to
increase further in the months ahead. Though effective
type 2 diabetes gene discovery remains very much in its
infancy, several important lessons are emerging.
Inherited susceptibility to common forms of type 2
diabetes derives from multiple genes of modest ef-
fect. The linkage approaches used in monogenic diabetes
are successful precisely because linkage analysis is intrin-
sically adept at ﬁnding highly penetrant variants, irrespec-
tive of allele frequency. Efforts to use similar linkage
approaches to identify type 2 diabetes–susceptibility genes
have met with only limited success, yielding few, if any,
consistently replicating signals (68). The lesson is clear:
common variants of large effect (what might once have
been called “major” genes) do not make an important
contribution to type 2 diabetes susceptibility.
Association-based approaches are far better suited to
identiﬁcation of signals of modest effect (69), and devel-
opment and exploitation of this methodology has had the
greatest impact on susceptibility gene discovery. Even so,
many of these discoveries have been hard-won. One
reason for this is that the “candidate” gene–based ap-
proach has proved, with notable exceptions (55,56), to be
an inefﬁcient route to susceptibility gene discovery; it is
only with the advent of functionally agnostic genome-wide
approaches that the ﬂoodgates have opened (70). Another
reason is that detection of the variants of modest effect
that appear to be responsible for much of type 2 diabetes
susceptibility (per-allele odds ratios [ORs] 1.10–1.40, for
risk-allele frequencies 10–90%) has required association
studies conducted in extremely large sample sizes (thou-
sands of individuals) (54). Variants within TCF7L2 have
TABLE 2
Summary details of the ﬁrst 17 loci with a proven role in type 2 diabetes susceptibility
Signal Chromosome
Representative
SNP
Risk allele
frequency
Effect
size How found Hypothecated biology
PPARG 3 rs1801282 0.85 1.23 Candidate
Adipocyte differentiation
and function
KCNJ11 11 rs5219 0.40 1.15 Candidate -Cell KATP channel
TCF7L2 10 rs7901695 0.40 1.37 Large-scale association Incretin signaling in the islet
HHEX 10 rs5015480 0.63 1.13 GWA Pancreatic development
SLC30A8 8 rs13266634 0.72 1.12 GWA
Zn transport in -cell insulin
granules
FTO 16 rs8050136 0.45 1.23 GWA
Hypothalamic effect on
weight regulation
CDKAL1 6 rs10946398 0.36 1.16 GWA -Cell function and mass
CDKN2A/B 9 rs10811661 0.86 1.19 GWA
Cell cycle regulation in the
-cell
IGF2BP2 3 rs4402960 0.35 1.11 GWA
mRNA processing in the
-cell
WFS1 4 rs10010131 0.60 1.11 Large-scale association
Endoplasmic reticulum
stress
TCF2/HNF1B 17 rs757210 0.43 1.08 Large-scale association
-Cell development and
function
JAZF1 7 rs864745 0.50 1.10 GWA
Transcriptional repression
in the islet
CDC123/CAMK1D 10 rs12779790 0.18 1.09 GWA
Cell cycle regulation
(CDC123)
TSPAN8 12 rs7961581 0.27 1.09 GWA Cell surface glycoprotein
THADA 2 rs7578597 0.90 1.12 GWA Apoptosis
ADAMTS9 3 rs4607103 0.76 1.06 GWA Metalloprotease
NOTCH2 1 rs10923931 0.11 1.11 GWA Pancreatic development
All loci have been shown to attain signiﬁcance levels consistent with genome-wide signiﬁcance in European populations. Note that in most
cases the single nucleotide polymorphisms (SNPs) denoted are unlikely to be causal. Effect size is given as the estimated OR per copy of the
risk allele. The biological processes listed are based on best available knowledge, but empirical data conﬁrming these are not yet available
for most. The data populating this table are derived mostly from refs. 55–67 and based on populations of European descent only.
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(57): the 15% of Europeans carrying two copies of the risk
allele are at approximately twice the lifetime risk of type 2
diabetes as the 40% who have none.
It is important to remember that for many of the newly
discovered susceptibility loci (57–67), all we have at
present is an initial association signal derived from an
incomplete survey of genome-wide common variation.
Deeper inspection of these association signals, using rese-
quencing to derive more complete inventories of local
genomic variation, and ﬁne mapping to explore the rela-
tionships between these variants and disease susceptibil-
ity may reveal that the variants of current interest are
merely weak surrogates for other stronger effects nearby.
It is also possible that future discovery efforts—targeting a
wider range of types of genome sequence variation than
the subset of common single nucleotide polymorphisms
captured by current genotyping platforms—will reveal
additional type 2 diabetes–susceptibility variants with
more impressive effect sizes (see below).
Nevertheless, it seems likely that many of the undiscov-
ered type 2 diabetes–susceptibility variants will have ef-
fects similar to, or smaller than, those found thus far; there
may well be scores (even hundreds) of these (71). Very
large sample sets (requiring collaboration between multi-
ple groups) will be required to detect them, to conﬁrm that
they are truly associated, and to identify the causal vari-
ants. Researchers planning to examine the consequences
of these variants on whole-body physiology, or on molec-
ular events in vitro, can expect that such low-penetrance
variants will often have equally subtle effects on interme-
diary metabolism and cellular function.
From a translational point of view, low-penetrance
variants may have limited value for individual prognosti-
cation (72) (see below). Nevertheless, they are already
providing valuable insights into the biology of type 2
diabetes (Table 2 and Fig. 4). Demonstrating that a partic-
ular variant has a genuine effect on type 2 diabetes
susceptibility generates the most direct evidence available
about pathways critical to the maintenance of normal
glucose homeostasis in humans. These pathways might,
with luck, be amenable to therapeutic or preventative
manipulation. From this perspective, the effect size of the
associated variant is irrelevant: more is likely to be learned
from discovering a weak (but genuine) genetic effect in an
entirely novel pathway than from a much larger effect that
highlights once again a process with an established role in
pathogenesis.
Most type 2 diabetes–susceptibility variants impact
on -cell function and/or mass. Individuals with type 2
diabetes typically display concomitant defects in both
insulin secretion and action. While it is axiomatic that
hyperglycemia implies some degree of relative or absolute
failure of -cell function, there has been a long-standing
debate about the relative importance (even “primacy”) of
the two processes in the pathogenesis of type 2 diabetes
(73). Notwithstanding the efforts of epidemiologists and
physiologists, this may be one debate where genetics
(precisely because of its focus on inherited rather than
acquired phenomena) may provide the answers.
The relative prevalence of mutations causal for mono-
genic forms of diabetes suggests that mutations in -cell–
related processes are a more frequent cause of severe
early-onset diabetes than those inﬂuencing insulin action
FIG. 4. Simpliﬁed schematic of the processes involved in genetic predisposition to type 2 diabetes. Assignments of loci to particular processes
are based on current knowledge of the presumed function of the best candidates within each signal and human physiological studies. These
assignments should be considered provisional until the causal variants have been identiﬁed and the molecular mechanisms through which they
act are established. Current evidence shows, however, that the majority of genes implicated in diabetes susceptibility act through effects on -cell
function and/or mass. This ﬁgure does not include the six type 2 diabetes–susceptibility loci reported most recently.
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of -cell function and insulin action in the general popu-
lation also hint at a preponderance of -cell effects (52).
Recent gene discovery efforts have provided further
evidence to support such assertions. Though, at this point,
the identity of some of the genes mechanistically respon-
sible for the association signals uncovered remains uncer-
tain, it remains possible to determine, through studies of
healthy populations, whether the type 2 diabetes–suscep-
tibility variants themselves are mediating their effects
through disruption of -cell function or insulin action.
With the exception of FTO (known to inﬂuence type 2
diabetes risk through a primary effect on adiposity) and
PPARG (long implicated in insulin action), all conﬁrmed
susceptibility alleles appear to exert their predominant
effect on diabetes pathogenesis through abrogation of
-cell function (or mass) (62,74–77). It would be wrong to
extrapolate too far: the known variants account for only a
small proportion of overall genetic risk, and the focus
on lean type 2 diabetes cases, which has characterized
several of the genome-wide association (GWA) studies
(58,59), may have generated a bias toward detection of
variants detrimental to -cell performance. Nonethe-
less, the picture that emerges is one where alterations of
-cell function seem to be playing the predominant role
with respect to the inherited component of disease
predisposition.
When it comes to further insights—to the identiﬁcation
of speciﬁc pathways responsible, for example—caution is
warranted. Colocalization of an association signal to the
same interval as a particular gene does not prove a causal
connection. In some instances, causal variants may be
inﬂuencing type 2 diabetes pathogenesis through remote
regulatory effects on genes whose coding sequences lie
some distance away. Indeed, several of the recently iden-
tiﬁed type 2 diabetes signals map to “gene deserts,” and
others (such as the association within the HHEX/KIF11/
IDE region on chromosome 10) map to regions containing
several good candidates (58–61). Until the causal variants
have been deﬁned, and unequivocal connections made to
the genes whose function and/or expression is altered, any
presumptions about the mechanisms involved must re-
main provisional. Having said that, certain themes are
emerging (Table 2 and Fig. 4). Perhaps the most exciting
involve the roles played by variants within the islet Zn
transporter (58) and cell-cycle regulators (59–62,67) in
type 2 diabetes predisposition. The latter discovery, in
particular, may help to resolve the controversy over the
part played by reduced -cell mass in the development of
diabetes (78).
Unexpected connections between diabetes and other
diseases. One of the most unexpected outcomes of large-
scale association approaches has been the identiﬁcation of
variants, and loci, that inﬂuence predisposition to multiple
diseases. These “pleiotropic” effects often cross conven-
tional nosological boundaries. In the case of type 2 diabe-
tes, the most compelling is the overlap with prostate
cancer. It has emerged that several of the genes implicated
in type 2 diabetes susceptibility (particularly TCF2/
HNF1B and JAZF1) are also involved in predisposition to
prostate cancer, a ﬁnding that hints at hitherto unsus-
pected common pathways inﬂuencing these two disease
processes (64,65,67). Since the predisposition effects seem
to lie in opposing directions, this ﬁnding also highlights the
risk that efforts at pharmaceutical modulation of this
pathway designed to beneﬁt diabetes may have adverse
consequences for cancer risk.
A further example concerns the region of type 2 diabe-
tes susceptibility mapped to chromosome 9, in the vicinity
of the CDKN2A/2B genes (59–61). Not only does this
region harbor at least two distinct type 2 diabetes–suscep-
tibility signals, it also contains a third, statistically inde-
pendent, signal with a profound effect on coronary artery
disease risk (79–81) and aneurysm formation (82). Sur-
prisingly, the diabetes and vascular association signals
involve quite distinct sets of variants, though these may act
through modulation of similar molecular pathways. In the
case of type 2 diabetes, this most plausibly involves an
effect on -cell regeneration mediated by CDKN2A over-
expression (83). Since loss of CDKN2A expression is a
common feature of many cancers, this may represent
another instance of molecular events with reciprocal
effects on cancer and diabetes risk.
The common variants so far uncovered have limited
capacity to provide individual prediction. In analysis
of large subject groups, it can be shown that the known
type 2 diabetes–susceptibility variants inﬂuence clinically
relevant phenotypes such as disease progression (84), risk
of complications, and therapeutic response (85). However,
it does not follow that those differences will be sufﬁcient
to provide clinically relevant information where individual
patients are concerned. Indeed, the modest effect sizes of
the variants identiﬁed to date mean that their individual
impact is likely to be limited.
This is best illustrated by considering variants in
TCF7L2 (57). GWA studies have demonstrated that vari-
ants in this gene have the strongest effect on diabetes risk
currently known, and a genetic test is commercially avail-
able. Assuming an average lifetime risk of type 2 diabetes
of 10%, someone with no copies of the risk allele would
(all else being equal) ﬁnd that ﬁgure falling to 7.5%,
whereas the lifetime risk for an individual with two copies
increases to 14.5%. It is not yet clear that personal infor-
mation of this kind (particularly when other pertinent
factors such as an individual’s age, ethnicity, family his-
tory, and BMI are not explicitly taken into account) will
lead individuals toward beneﬁcial changes in health-re-
lated behaviors (86) or alterations in their clinical manage-
ment. Indeed, if such information were to be poorly
presented, there is a danger that overestimation of the
deterministic qualities of genetic information could moti-
vate individuals toward counterproductive changes to
their lifestyle (through unwarranted fatalism or feelings of
personal immunity).
Of course, individual small effects can amount to more
when considered collectively, and it is true that genetic
testing (for the 17 known genes, for example) can identify
subsets of individuals who have inherited particularly high
or low numbers of risk alleles and therefore have marked
differences in individual risk (87). However, the numbers
of individuals in these “extreme” high- and low-risk groups
are comparatively small, and for many, their risk will
already be obvious through conventional factors (family
history, BMI, and previous gestational diabetes, for exam-
ple). When the information from the known type 2 diabe-
tes–susceptibility variants is examined using approaches
such as receiver-operating curve analysis, which are better
suited for evaluating the performance of diagnostic tests at
the population level, the results look far less spectacular
(72,87).
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prediction of type 2 diabetes and its complications will
require three developments. The ﬁrst involves identiﬁca-
tion of a growing number of risk variants that, collectively,
deliver greater predictive and discriminative performance
than the subset thus far known. The second involves
understanding how genetic information can be combined
with other conventional risk factors (and possibly with
non-DNA–based biomarkers, as these emerge) to provide
a more accurate assessment of individual risk. It should be
kept in mind that susceptibility genotype information will
not be orthogonal to those traditional factors, since sev-
eral of them (such as ethnicity, family history, and BMI)
capture overlapping genetic information. The third devel-
opment will be evidence that imparting such information
results in clinically meaningful differences in individual
behavior or provides a more rational basis for therapeutic
or preventative interventions.
A GLIMPSE INTO THE FUTURE
Getting from the extremes to a comprehensive view
of diabetes genetics. As described above, success in the
identiﬁcation of genes impacting on individual risk of
diabetes has come from two distinct approaches to gene
discovery. The ﬁrst, linkage mapping within monogenic
and syndromic families, has delivered causal variants that
are rare but highly penetrant. The second, large-scale
association mapping, is now yielding growing numbers of
common variants: these have, at best, modest effect sizes
and low penetrance. Several genes are featured in the lists
generated by both approaches. For example, mutations in
KCNJ11, PPARG, WFS1, and TCF2 (HNF1B) are causal
for syndromic and/or monogenic forms of diabetes, while
common variants in these same genes inﬂuence predispo-
sition to typical type 2 diabetes (55,56,64–66). While
common variants in GCK (another gene causal for MODY)
do not inﬂuence type 2 diabetes risk per se, they have a
clear impact on fasting glucose levels within the popula-
tion (88).
Of course, none of this should come as a surprise. Once
a gene has been shown to harbor one variant associated
with, or causal for, a diabetes-like phenotype, it becomes
far more likely that other nearby variants (provided they
exert some effect on the expression and/or function of the
gene) will also have a detectable phenotypic effect. By
the same token, the genotype-phenotype relationships
revealed by these gene discovery efforts highlight the
pathways involved as prime candidates for beneﬁcial
therapeutic or preventative manipulation, a view rein-
forced by the fact that at least two of the genes involved in
both monogenic and multifactorial forms of diabetes
(PPARG, KCNJ11) encode the targets of proven diabetes
drugs.
However, it should be obvious that these two “ﬂavors”
of polymorphism—rare and highly penetrant on the one
hand and low penetrant on the other—are not the only
options when it comes to the variants that might inﬂuence
disease susceptibility. It seems probable, even likely, that
between these extremes lies a class of medium frequency,
medium penetrance variants that have until now escaped
the gaze of the gene mappers.
Such variants would have penetrances too low to gen-
erate Mendelian patterns of segregation and frequencies
too low to be covered by current GWA approaches.
Despite this, such variants have particularly attractive
translational properties. For example, a variant where the
risk allele has a frequency of 1% and produces in a
per-allele OR of 3 would provide greater predictive
power than the known variants in TCF7L2. Variants with
such characteristics are increasingly being reported in
other disease states (breast cancer and hyperlipidemia)
(89,90) and have even been reported in type 2 diabetes
(91). In principle, just 30 such variants across the genome
could explain the observed familial aggregation of type 2
diabetes in a way that the current set of common, low-
penetrance variants cannot. Such a pool of variants would
also provide an excellent tool for individual diabetes-risk
prediction, generating a discriminative accuracy on receiver-
operating characteristic analysis close to 80%. The advent
of new high-throughput sequencing technologies, allied to
large-scale association analysis, brings variants in this
class within the range of genetic discovery and should
allow researchers to evaluate the contribution to disease
susceptibility attributable to variants that lie between the
extremes where previous attention has been focused.
There are many other challenges to be faced and oppor-
tunities to be realized in the years ahead. The ﬁrst of these
lies in extending the range of variants that are accessible
to scrutiny, beyond the low-frequency variants referred to
in the previous paragraph, to a systematic evaluation of
structural polymorphisms (insertions, deletions, and du-
plications) and variants that inﬂuence methylation status
(92). Another lies in characterizing the association signals
that have been found: large-scale resequencing and ﬁne-
mapping strategies will be required to recover the full
allelic spectrum of causal variants and thereby obtain the
most precise quantiﬁcation of the genetic effects attribut-
able to each locus. The part played by nonadditive inter-
actions between different genetic loci and between
susceptibility variants and environmental exposures needs
to be charted, and discovery and replication studies need
to be extended beyond the European populations that
have been the focus of much of the current research.
Moving beyond genetics, there is work to be done to
understand the novel (molecular, cellular, and physiolog-
ical) biology revealed by these discoveries. If, as seems
probable, many of the causal variants lie in noncoding
regions, often some distance from the nearest coding
sequence, they will often have subtle, spatially and/or
temporally restricted effects. In such circumstances, gath-
ering experimental evidence of their functional impact will
be seriously difﬁcult.
The ﬁnal challenge lies in placing gene discovery into
translational context. The clinical utility and validity of
genetic diagnostics are already established in monogenic
diabetes, where such testing can inﬂuence clinical practice
and treatment. However, diagnostic genetic testing, still
underutilized by most diabetologists, and further research,
development, and education are required. It is a major
challenge to establish how to use knowledge from the
identiﬁcation of predisposing polymorphisms in type 2
diabetes to improve the care of the diabetic patient.
Deﬁnition of the underlying polymorphisms and genes is
but a ﬁrst step on this road.
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